Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers

Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers is a phase 3, randomised interventional study registered as NCT02497820 by Tel-Aviv Sourasky Medical Center, with a registry enrolment figure of 1800 participants, started 2016-09 and due to reach its primary completion in 2027-09. Interventions recorded: Aspirin. Conditions listed: Lynch Syndrome I (Site-specific Colonic Cancer). Primary outcome: cancer preventive properties of enteric coated aspirin in Lynch syndrome are dose sensitive by comparing overall cumulative Lynch syndrome cancer. Sites: Israel. No results are recorded here; the registry entry is the source.